Clarivate Q3 Organic Revenue Rises 0.4% as Net Loss Widens

Clarivate reported third-quarter results on 2026년 11월 3일, showing continuing-operations revenue of $481.6 million for the quarter ended 2026년 9월 30일, down 9.2% from $530.3 million in the third quarter of 2025, while organic revenue rose 0.4%. Net loss including Life Sciences & Healthcare, the segment subsequently divested, widened to $80.8 million, or $0.13 per diluted share, from $28.3 million, or $0.04.

The reported revenue decline primarily reflected inorganic disposals, while the wider loss was driven by a $62.2 million non-cash goodwill impairment charge for Life Sciences & Healthcare. For continuing operations, adjusted EBITDA, which Clarivate bases on net income before interest, taxes, depreciation and amortization with additional adjustments for items it does not consider indicative of ongoing performance, slipped to $218.2 million from $222.2 million. The adjusted EBITDA margin nevertheless increased to 45.3% from 41.9%.

Recurring Revenue Offsets Transactional Declines

Subscription revenue reached $338.3 million, with organic growth of 1.5% driven primarily by new sales and pricing actions. Re-occurring revenue reached $105.8 million, growing 0.7% organically on higher Intellectual Property volumes. Combined recurring revenue, which comprises those two streams, totaled $444.1 million against $441.2 million in the prior-year quarter and grew 1.3% organically.

Transactional revenue dropped by $51.6 million to $37.5 million, primarily because of product-group wind-downs within Academia & Government. Its 12.4% organic decline also reflected lower activity across both segments and, in part, customer migration toward higher-margin subscription products as Clarivate concentrates on recurring revenue.

Academia & Government revenue fell to $286.9 million from $332.5 million, with disposals accounting for a 14.1-percentage-point drag, but organic revenue increased 0.9%. Intellectual Property revenue was $194.7 million versus $197.8 million, with organic revenue down 0.4%.

Divestiture Proceeds Meet a Large Debt Load

Clarivate completed the sale of Life Sciences & Healthcare to Altaris on 2026년 10월 6일, in a transaction valued at $600 million and first announced on 2026년 7월 6일. Net cash proceeds were $488.4 million. The remaining portfolio consists of Academia & Government and Intellectual Property, and the stated intention is to use the transaction proceeds to reduce debt and strengthen the balance sheet.

Total debt outstanding stood at $4.1761 billion on 2026년 9월 30일, down $293.8 million from the prior year. The reduction reflected a $100 million accelerated repayment that fully redeemed senior secured notes due 2026년 11월, plus $192.6 million of principal retired through repurchases of senior secured notes due 2028 and senior notes due 2029 at an approximate 5% discount to par. Because the sale closed after quarter-end, that debt balance does not show any subsequent application of the proceeds.

Cash generation was weaker during the nine months before the sale closed. Operating cash flow including discontinued operations fell to $399.0 million from $468.6 million, while free cash flow, which Clarivate defines as operating cash flow less capital expenditures, declined to $233.1 million from $276.1 million.

Outlook Calls for Faster Recurring Growth

Clarivate’s reset outlook assumes no further acquisitions, divestitures or unanticipated events:

The revenue and adjusted EBITDA targets exclude discontinued operations. Full-year free cash flow includes them for the first nine months but excludes them for the fourth quarter.

The fourth-quarter outlook calls for faster recurring organic growth than the 1.3% delivered in the third quarter. With Life Sciences & Healthcare gone, the central financial question is whether faster recurring growth can translate into stronger cash generation while the divestiture proceeds are applied to reducing the remaining debt.